|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC9C1 |
Gene summary for SLC9C1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC9C1 | Gene ID | 285335 |
| Gene name | solute carrier family 9 member C1 | |
| Gene Alias | NHE | |
| Cytomap | 3q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q4G0N8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 285335 | SLC9C1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.58e-09 | 6.09e-01 | -0.0811 |
| 285335 | SLC9C1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.28e-12 | 7.75e-01 | -0.1088 |
| 285335 | SLC9C1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.54e-26 | 7.89e-01 | -0.1954 |
| 285335 | SLC9C1 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.10e-09 | 1.19e+00 | -0.2602 |
| 285335 | SLC9C1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.08e-07 | 1.11e+00 | -0.2196 |
| 285335 | SLC9C1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.64e-03 | 4.78e-01 | -0.1207 |
| 285335 | SLC9C1 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.09e-07 | 6.03e-01 | -0.1526 |
| 285335 | SLC9C1 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.36e-14 | 5.28e-01 | -0.1464 |
| 285335 | SLC9C1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.58e-11 | 5.24e-01 | -0.1001 |
| 285335 | SLC9C1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.84e-07 | 4.57e-01 | -0.059 |
| 285335 | SLC9C1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 5.58e-05 | 5.15e-01 | 0.0588 |
| 285335 | SLC9C1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.96e-04 | 3.10e-01 | 0.294 |
| 285335 | SLC9C1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.26e-04 | 3.28e-01 | 0.3859 |
| 285335 | SLC9C1 | A015-C-203 | Human | Colorectum | FAP | 2.46e-03 | -1.03e-01 | -0.1294 |
| 285335 | SLC9C1 | A015-C-104 | Human | Colorectum | FAP | 1.66e-02 | -9.67e-02 | -0.1899 |
| 285335 | SLC9C1 | A002-C-116 | Human | Colorectum | FAP | 2.34e-02 | -1.04e-01 | -0.0452 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1902600 | Colorectum | AD | proton transmembrane transport | 66/3918 | 157/18723 | 1.59e-09 | 1.17e-07 | 66 |
| GO:0030004 | Colorectum | AD | cellular monovalent inorganic cation homeostasis | 36/3918 | 103/18723 | 6.80e-04 | 6.95e-03 | 36 |
| GO:0030641 | Colorectum | AD | regulation of cellular pH | 29/3918 | 81/18723 | 1.42e-03 | 1.22e-02 | 29 |
| GO:0051453 | Colorectum | AD | regulation of intracellular pH | 26/3918 | 75/18723 | 4.04e-03 | 2.82e-02 | 26 |
| GO:0006885 | Colorectum | AD | regulation of pH | 30/3918 | 91/18723 | 4.95e-03 | 3.32e-02 | 30 |
| GO:0055067 | Colorectum | AD | monovalent inorganic cation homeostasis | 45/3918 | 151/18723 | 6.19e-03 | 3.88e-02 | 45 |
| GO:19026001 | Colorectum | SER | proton transmembrane transport | 60/2897 | 157/18723 | 3.12e-12 | 7.08e-10 | 60 |
| GO:00300041 | Colorectum | SER | cellular monovalent inorganic cation homeostasis | 31/2897 | 103/18723 | 1.31e-04 | 2.66e-03 | 31 |
| GO:00306411 | Colorectum | SER | regulation of cellular pH | 24/2897 | 81/18723 | 9.20e-04 | 1.11e-02 | 24 |
| GO:00550671 | Colorectum | SER | monovalent inorganic cation homeostasis | 37/2897 | 151/18723 | 2.48e-03 | 2.33e-02 | 37 |
| GO:00514531 | Colorectum | SER | regulation of intracellular pH | 21/2897 | 75/18723 | 3.97e-03 | 3.26e-02 | 21 |
| GO:00068851 | Colorectum | SER | regulation of pH | 24/2897 | 91/18723 | 5.03e-03 | 3.88e-02 | 24 |
| GO:19026002 | Colorectum | MSS | proton transmembrane transport | 57/3467 | 157/18723 | 1.00e-07 | 4.81e-06 | 57 |
| GO:00300042 | Colorectum | MSS | cellular monovalent inorganic cation homeostasis | 31/3467 | 103/18723 | 2.94e-03 | 2.27e-02 | 31 |
| GO:00306412 | Colorectum | MSS | regulation of cellular pH | 25/3467 | 81/18723 | 4.97e-03 | 3.46e-02 | 25 |
| GO:0035725 | Colorectum | FAP | sodium ion transmembrane transport | 44/2622 | 178/18723 | 9.31e-05 | 1.60e-03 | 44 |
| GO:19026004 | Colorectum | FAP | proton transmembrane transport | 39/2622 | 157/18723 | 2.03e-04 | 2.92e-03 | 39 |
| GO:00300043 | Colorectum | FAP | cellular monovalent inorganic cation homeostasis | 28/2622 | 103/18723 | 3.23e-04 | 4.15e-03 | 28 |
| GO:0006814 | Colorectum | FAP | sodium ion transport | 54/2622 | 245/18723 | 3.98e-04 | 4.85e-03 | 54 |
| GO:00514532 | Colorectum | FAP | regulation of intracellular pH | 22/2622 | 75/18723 | 4.38e-04 | 5.21e-03 | 22 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC9C1 | SNV | Missense_Mutation | novel | c.1998G>C | p.Met666Ile | p.M666I | Q4G0N8 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| SLC9C1 | SNV | Missense_Mutation | c.951N>A | p.His317Gln | p.H317Q | Q4G0N8 | protein_coding | tolerated(0.58) | benign(0.185) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
| SLC9C1 | SNV | Missense_Mutation | c.589N>A | p.Gln197Lys | p.Q197K | Q4G0N8 | protein_coding | tolerated(0.43) | benign(0.027) | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
| SLC9C1 | SNV | Missense_Mutation | c.692N>C | p.Gln231Pro | p.Q231P | Q4G0N8 | protein_coding | deleterious(0.01) | possibly_damaging(0.834) | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| SLC9C1 | SNV | Missense_Mutation | c.1513N>A | p.Glu505Lys | p.E505K | Q4G0N8 | protein_coding | deleterious(0.01) | possibly_damaging(0.612) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SLC9C1 | SNV | Missense_Mutation | novel | c.2767N>C | p.Gly923Arg | p.G923R | Q4G0N8 | protein_coding | tolerated(0.19) | possibly_damaging(0.454) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
| SLC9C1 | SNV | Missense_Mutation | c.101N>T | p.Arg34Leu | p.R34L | Q4G0N8 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC9C1 | SNV | Missense_Mutation | c.2571C>G | p.Ile857Met | p.I857M | Q4G0N8 | protein_coding | deleterious(0.02) | possibly_damaging(0.564) | TCGA-AR-A1AU-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| SLC9C1 | SNV | Missense_Mutation | novel | c.604N>T | p.His202Tyr | p.H202Y | Q4G0N8 | protein_coding | tolerated(0.67) | benign(0.001) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| SLC9C1 | SNV | Missense_Mutation | c.373C>A | p.His125Asn | p.H125N | Q4G0N8 | protein_coding | deleterious(0.01) | benign(0.006) | TCGA-EW-A1J6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |